Search Results "#Setmelanotide"

Blogs

arrow_forward View More Results
Proopiomelanocortin Deficiency Treatment Market: How Is Setmelanotide Therapy Becoming the Fastest-Growing Therapeutic Intervention?
Posted by Surbhi on July 24 2026 at 05:41 PM   public
Setmelanotide (IMCIVREE) — the first FDA-approved melanocortin-4 receptor (MC4R) agonist specifically indicated for proopiomelanocortin (POMC) deficiency-associated obesity representing the targe...
Proopiomelanocortin Deficiency Treatment Market: How Is Melanocortin-4 Receptor Agonism Redefining Monogenic Obesity Therapeutics?
Posted by Surbhi on July 02 2026 at 05:36 PM   public
Proopiomelanocortin deficiency — the ultra-rare monogenic obesity disorder caused by loss-of-function mutations in the POMC gene resulting in early-onset severe obesity, hyperphagia, adrenal insu...
arrow_forward